PreMarket22May_Nasdaq, page-6

First 30 mins has been largely a Plus, but as Foxhead put it.. early days..

RE: Valuation of the Cvac oportunity: My 2 cents: There are 2 opportunities PRR would have
1. Development with Partner: This one will be determined by the cost of production vis a vis competetive products available and the overall addressable market size. Clinical results will matter with more bigger test market results and reputation of the development co... lets say brand equity of the Development partner.

2. A sell off of Licence all together for Development and the rest
This could be a agreed $$$$$$$ value ( value to be determined by Prima Board based on the above and more factors which they would be expert in determining.) ideally should call for an EGM and approval of share holders. This would have a immediate impact on pretty much everything, SP, Balance Sheet and Future Funds raising and that may not be necessary.